NIH GUIDE, Volume 23, Number 32, August 26, 1994

P.T. 34, FF


  Biomedical Research, Multidiscipl 

National Institute on Drug Abuse


The purpose of this notice is to inform the research community that the

National Institute on Drug Abuse (NIDA) will accept competing

continuation (renewal) applications for participation in the Minority

Institutions Research Development Program (MIRDP).  The MIRDP was

designed to increase the capacity of predominantly minority

institutions and their faculty to conduct alcohol, drug abuse, and

mental health research.  NIDA is accepting renewal applications

specific to drug abuse research.


Renewal applications are to be submitted on the grant application form

PHS 398 (rev. 9/91), with a cover letter indicating the request for

renewal.  The application face page must also indicate across top

margin "RENEWAL APPLICATION" and must be sent to:

Division of Research Grants

National Institutes of Health

Westwood Building, Room 240

Bethesda, MD  20892**

Renewals must be received in accordance with the standard receipt dates

for competing continuation (renewal) applications (i.e., March 1, July

1, and November 1).

Competing continuation (renewal) applications must include a progress

report containing the following information:

1.  Summary of institution's research projects developed or expanded

through the MIRDP award;

2.  Outline of drug abuse-related research development activities by

institution, faculty and staff;

3.  Demonstration of increased involvement or interest by minority

students in drug-related research projects or pursuing drug-related

research careers through participation in MIRDP-sponsored activities;

4.  Review of any infrastructure enhancements to institution, including

faculty ability to conduct drug abuse-related research.  Include any

examples of laboratory improvement, faculty development, data and

statistical analysis capability, resource development, and the like.

The competing continuation (renewal) application should, as in the

original:  (1) assess the current institutional and faculty capacity to

conduct drug-related research, (2) identify unmet needs, and (3)

describe the activities to further develop the institutional

infrastructure and faculty capacity to conduct drug research.  The

continuation application should include both an institutional research

development program and one or more individual investigator projects.

The applicant must submit a budget detailing the costs associated with

the proposed renewal, including personnel (percent effort, rate, and

fringe benefits), supplies and equipment, shipping and handling

expenses, laboratory costs, and expenses for study subjects including

travel reimbursements, if applicable.

The NIH peer review process will be used.  A NIDA study section with

expertise in the subject area will evaluate the scientific merit of the

application, using evaluation criteria described in the MIRDP program

announcement dated April 1989.


Questions regarding programmatic aspects and matters pertaining to the

review of the application may be directed to:

Lula A. Beatty, Ph.D.

Special Populations Office

National Institute on Drug Abuse

5600 Fishers Lane

Parklawn Building, Room 10A08

Rockville, MD  20857

Telephone:  (301) 443-0441

Questions regarding administrative or budgetary issues may be directed


Gary Fleming

Grants Management Branch

National Institute on Drug Abuse

5600 Fishers Lane

Parklawn Building, Room 8A54

Rockville, MD  20857

Telephone:  (301) 443-6710


Return to 1994 Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.